{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:38:10Z","timestamp":1780393090837,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.clgc.2019.11.006","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T11:50:35Z","timestamp":1575460235000},"page":"e277-e283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8952-3873","authenticated-orcid":false,"given":"Sebastian","family":"Nachbargauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bruchbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harun","family":"Fajkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesut","family":"Remzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Schmidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.11.006_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.11.006_bib2","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.11.006_bib3","first-page":"327","article-title":"In\u00a0vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.11.006_bib4","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","article-title":"Resistance to targeted therapy in renal-cell carcinoma","volume":"10","author":"Rini","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.11.006_bib5","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/onc.2015.343","article-title":"Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma","volume":"35","author":"Zhou","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.clgc.2019.11.006_bib6","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.11.006_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.11.006_bib8","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.11.006_bib9","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1535-7163.MCT-09-1106","article-title":"Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study","volume":"9","author":"Hammers","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2019.11.006_bib10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/MOU.0000000000000206","article-title":"The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma","volume":"25","author":"Oudard","year":"2015","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.clgc.2019.11.006_bib11","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1002\/cncr.25583","article-title":"Sunitinib rechallenge in metastatic renal cell carcinoma patients","volume":"116","author":"Zama","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.11.006_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2016.04.003","article-title":"Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma\u2014results of the rechallenge with sunitinib in metastatic RCC (RESUME) study","volume":"62","author":"Oudard","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.11.006_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.11.006_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2016.10.006","article-title":"Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR","volume":"51","author":"Sartore-Bianchi","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"suppl 6","key":"10.1016\/j.clgc.2019.11.006_bib15","doi-asserted-by":"crossref","first-page":"Vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.11.006_bib16","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/j.cllc.2015.04.006","article-title":"Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum\/etoposide rechallenge: a multi-institutional retrospective analysis","volume":"16","author":"Genestreti","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.clgc.2019.11.006_bib17","doi-asserted-by":"crossref","first-page":"49713","DOI":"10.18632\/oncotarget.17923","article-title":"HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1\u03b1 and HIF-2\u03b1 balance in renal cell carcinoma","volume":"8","author":"Lai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2019.11.006_bib18","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.11.006_bib19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jpainsymman.2015.02.007","article-title":"Ongoing screening and treatment to potentially reduce tyrosine kinase inhibitor-related fatigue in renal cell carcinoma","volume":"50","author":"Anand","year":"2015","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.clgc.2019.11.006_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000100450","article-title":"Symptoms in the lives of terminal cancer patients: which is the most important?","volume":"71","author":"Kwon","year":"2006","journal-title":"Oncology"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731930357X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731930357X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:33:13Z","timestamp":1761564793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876731930357X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S155876731930357X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.11.006","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}